CommercialCoverageMedium impact
06.02.32d, Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)
Independence Blue Cross·Oncology, General Surgery·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued Policy 06.02.32d regarding multigene expression assays for predicting recurrence in colon cancer, effective March 5, 2025. The billing team must review coverage criteria, medical necessity requirements, and any prior authorization mandates for these molecular oncology tests to ensure compliant claim submission.
Action Required
By March 5, 2025: Billing team must obtain and review the full text of Policy 06.02.32d from the Independence Administrators policy portal. Identify specific CPT/HCPCS codes for multigene expression assays (likely in 81000-81599 range). Determine if prior authorization is required and update billing system rules accordingly. Notify oncology and colorectal surgery providers of any new documentation requirements or authorization workflows. Update claim submission protocols to reflect the reissued policy requirements. Verify that all colon cancer recurrence prediction assay claims submitted on or after March 5, 2025 comply with this policy to prevent denials.